BFM
LFCR icon

Boothbay Fund Management’s Lifecore Biomedical LFCR Stock Holding History

Boothbay Fund Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,964
Closed -$221K – 2180
2025
Q3 		$221K Buy
+29,964
New +$227K ﹤0.01% 1608
2025
Q1 		– Sell
-87,142
Closed -$647K – 1606
2024
Q4 		$647K Sell
87,142
-100,004
-53% -$639K 0.02% 788
2024
Q3 		$923K Buy
187,146
+174,896
+1,428% +$914K 0.02% 781
2024
Q2 		$62.8K Sell
12,250
-57,854
-83% -$343K ﹤0.01% 1393
2024
Q1 		$372K Buy
70,104
+58,581
+508% +$419K 0.01% 1126
2023
Q4 		$71.3K Buy
+11,523
New +$80K ﹤0.01% 1482

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Boothbay Fund Management's LFCR Position: Q4 2025 in Review

Boothbay Fund Management sold out of Lifecore Biomedical (LFCR) in Q4 2025, closing a stake of 29,964 shares — an estimated $221K sold.

Boothbay Fund Management first reported a position in LFCR in Q4 2023 and held it in 6 quarters. The position peaked at $923K in Q3 2024. 103 funds tracked by Wall St. Rank hold LFCR as of Q4 2025.

  • Boothbay Fund Management reported no remaining Lifecore Biomedical position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 29,964 Lifecore Biomedical shares in Q4 2025, an estimated $221K.
  • Boothbay Fund Management first reported a position in Lifecore Biomedical in Q4 2023 and held it in 6 quarters.
  • Boothbay Fund Management's Lifecore Biomedical position peaked at $923K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.